Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,422 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of the firm’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the completion of the sale, the chief operating officer now owns 272,044 shares of the company’s stock, valued at approximately $13,648,447.48. This trade represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $52.23 on Tuesday. The business has a 50-day moving average of $47.62 and a two-hundred day moving average of $46.37. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a market capitalization of $3.10 billion, a P/E ratio of -14.51 and a beta of 1.85.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA lifted its position in Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after acquiring an additional 20,035 shares in the last quarter. Barclays PLC grew its holdings in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. FMR LLC raised its position in Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the last quarter. Avanza Fonder AB bought a new stake in Twist Bioscience in the 4th quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets boosted its position in Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after acquiring an additional 21,357 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TWST shares. Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Robert W. Baird upped their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank boosted their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.